5-lipoxygenase: a rational target for therapy of inflammatory bowel disease?
- 28 February 1990
- journal article
- review article
- Published by Elsevier in Trends in Pharmacological Sciences
- Vol. 11 (2) , 51-53
- https://doi.org/10.1016/0165-6147(90)90313-w
Abstract
No abstract availableKeywords
This publication has 14 references indexed in Scilit:
- The effect of leukotriene-B4 receptor antagonist, SC-41930, on acetic acid-induced colonic inflammationInflammation Research, 1989
- L-663,536 (MK-886) (3-[1-(4-chlorobenzyl)-3-t-butyl-thio-5-isopropylindol-2-yl]-2,2-dimethylpropanoic acid), a novel, orally active leukotriene biosynthesis inhibitorCanadian Journal of Physiology and Pharmacology, 1989
- 5-Aminosalicylic acid concentration in mucosal interstitium of cat small and large intestineDigestive Diseases and Sciences, 1989
- Inhibition of leukotriene synthesis markedly accelerates healing in a rat model of inflammatory bowel diseaseGastroenterology, 1989
- Chemotactic activity in inflammatory bowel diseaseDigestive Diseases and Sciences, 1987
- Increased Intestinal Permeability in Patients with Crohn's Disease and Their RelativesAnnals of Internal Medicine, 1986
- The immunologic basis of inflammatory bowel diseaseJournal of Clinical Immunology, 1986
- Effects of topical 5-aminosalicylic acid and prednisolone on prostaglandin E2 and leukotriene B4 levels determined by equilibrium in vivo dialysis of rectum in relapsing ulcerative colitisGastroenterology, 1986
- Arachidonic acid metabolites and their role in inflammatory bowel diseaseGastroenterology, 1985
- Sulfasalazine inhibits the synthesis of chemotactic lipids by neutrophils.Journal of Clinical Investigation, 1982